卵巢上皮癌间隔减瘤术后辅助化疗给药方式重要吗？

　　Does modality of adjuvant chemotherapy administration after interval surgical debulking matter in epithelial ovarian cancer?

　　N. Almutairi, T. Le

　　Gyncologic Oncology, Ottawa Hospital, Ottawa, ON, Canada

　　Objectives: To study the role of intraperitoneal (IP) chemotherapy after neoadjuvant chemotherapy and interval surgical debulking.

　　Method: All neoadjuvant treated epithelial ovarian cancer patients were retrospectively reviewed from 2007-9. Demographics, disease related and survival outcome data were abstracted from electronic medical records. Chi Square statistics were used for categorical variables. Cox regression was used to model progression free survival adjusting for age, residual status, and use of IP chemotherapy. Log rank statistic was used to compare survivals between IP and IV treated patients after surgery. All p values less than 0.05 were considered to be statistical significant.

　　Results: 65 patients were reviewed. Median age was 63yo. The majority had stage 3/4 disease with serous histology. Optimal residual was achieved in 52% of patients. Half of these patients went on to be treated with IP chemotherapy. Median follow up was 26.2 months. Fifty one patients had progressed with the median progression free survival (PFS) of 14.5 months. Use of IP chemotherapy post interval debulking surgery was not significantly associated with PFS (HR 0.82 95% CI 0.31-2.22 p=0.70). Estimated median overall survival was 37.8 mos (95% CI 29.9-45.7) in IV treated only versus 48.1 mos (95% CI 37.9-58.3) in IP treated patients (p=0.162).

　　Conclusion: IP chemotherapy was not statistically significant associated with survivals in neoadjuvant treated ovarian cancer in our early experience. The role of IP chemotherapy after neoadjuvant chemotherapy need to be further defined pending on the final mature result of OV 21 study currently accrual patients.

　　更多精彩内容，请点击专题报道：http://zt.cmt.com.cn/zt/igcs2012/index.html